Endonovo Therapeutics, Inc. announced its inclusion on the Federal Supply Schedule (FSS) for SofPulse®? Pulsed Electro Magnetic Field (PEMF) medical devices for distribution throughout the Federal healthcare supply channels. The listing was spearheaded by Endonovo's partner, Academy Medical Inc, a Service-Disabled Veteran-Owned Small Business (SDVOSB) government reseller.

Academy Medical's efforts to secure SofPulse®? on the exclusive FSS is the first of many strategic moves for Endonovo to streamline the distribution of its medical products throughout government healthcare systems.SofPulse® is an FDA-Cleared medical device which is recognized for its exceptional efficacy for postoperative reduction of pain and edema (inflammation). Clinical studies and patient use have shown that PEMF has the capacity to alleviate pain, promote recovery and enhance overall patient well-being.

As SofPulse® is non-invasive, opioid-free and with its potential to speed up recovery, it sets it apart in the medical technology landscape. The inclusion of SofPulse® on the FSS signifies not only a stamp of approval from Federal authorities, but further affirms the Company?s objective of having SofPulse® widely distributed within the government healthcare sectors. SofPulse® listing on the FSS places its proven PEMF recovery technology at the forefront of distribution, paving the way for exponential growth within the Veterans Administration (VA) and Department of Defense as well as other governmental healthcare sectors.

The VA utilizes the FSS to make available a wide range of authorized products and services on an ongoing basis. As Endonovo navigates this new phase of Federal expansion, the Company remains resolute in its mission to enhance patient care for military heroes and their families. Expanding Federal contracts is important to positioning Endonovo to seize anticipated expansion for active and non-active military personnel surgical, medical and wound care needs.

Through the FSS, SofPulse® will gain increased visibility to serve a wider range of patients., strengthening its position as a non-opioid medical solution within the Government medical technology sector. Endonovo has identified numerous governmental healthcare contracts for the expansion of distribution throughout the government healthcare sectors. Through Academy Medical, additional future government contracts targeted include: Strategic Acquisition Center (SAC), National Acquisition Center (NAC) and the defense agencies and Department of Defense Field Activities (DAFA) distribution schedules.

Each federal contract being targeted affords Endonovo the opportunity allows Endonovo and SofPulse to reach a broader audience, including hundreds of federal healthcare facilities throughout the US and the world. The Company aims to leverage the power and influence of the Federal government's buying process to provide SofPulse® to healthcare facilities and patients not currently being serviced.